What is the appropriate management and work‑up for Budd‑Chiari syndrome?

Management and Work-up of Budd-Chiari Syndrome

All patients with Budd-Chiari syndrome should receive immediate indefinite anticoagulation with low molecular weight heparin (LMWH) for 5-7 days bridged to vitamin K antagonist (VKA) targeting INR 2-3, followed by a stepwise therapeutic algorithm progressing from medical therapy to angioplasty/stenting, then TIPS, and finally liver transplantation based on treatment response. 1

Diagnostic Work-up

Initial Imaging

• Doppler ultrasound is the first-line diagnostic test with >75% sensitivity for detecting hepatic venous outflow obstruction 1
• If Doppler is inconclusive or an experienced sonographer unavailable, proceed to MRI or CT imaging for diagnostic confirmation 1
• Venography is indicated when diagnosis remains uncertain or to characterize anatomy prior to interventional treatment 1
• Liver biopsy should be performed if imaging fails to demonstrate large vein obstruction, to assess for small hepatic vein thrombosis 1

Thrombophilia Evaluation

The most critical etiologic work-up focuses on identifying underlying prothrombotic conditions:

• Screen for myeloproliferative neoplasms (MPNs), particularly polycythemia vera—this is the most common cause in Western populations (50% of cases) 2
• Test for JAK2V617F mutation (present in 82.5% of MPN-associated BCS) 2
• Evaluate for inherited thrombophilias (second most common cause at 18%) 2
• Consider oral contraceptive use as a risk factor 3

Stepwise Treatment Algorithm

Step 1: Medical Management (All Patients)

Anticoagulation must be initiated immediately upon diagnosis:

• Start LMWH for minimum 5-7 days 1
• Overlap with VKA, targeting INR 2-3 1
• Continue LMWH until INR therapeutic for two consecutive measurements 1
• Anticoagulation is lifelong and indefinite to prevent clot extension and recurrent thrombosis 1, 3

Treat the underlying prothrombotic disorder concurrently—early treatment of MPNs has demonstrated benefit in retrospective analyses 1

Manage portal hypertension complications (ascites, varices) using the same approach as cirrhotic patients 1

Important Caveat on Bleeding Risk

While older cohorts (1995-2005) reported bleeding complications in up to 50% of anticoagulated patients, more recent data (2005-2007) shows only 17% bleeding rates with improved anticoagulation management during procedures and adequate variceal prophylaxis 1. This should not deter anticoagulation.

Step 2: Angioplasty/Stenting (For Stenotic Lesions)

Proceed to angioplasty when partial or segmental stenoses are identified:

• Present in 60% of IVC obstruction cases and 25-30% of hepatic vein obstruction 1
• Angioplasty restores physiological venous drainage and may reverse disease 4
• Add stenting if angioplasty results are suboptimal or re-stenosis occurs 1
• This approach is particularly effective for membranous or short-segment occlusions common in Asian populations 4

Thrombolysis has limited but specific utility:

• Consider only for recent, incomplete thrombosis with local, early infusion combined with angioplasty/stenting 1
• Be aware that complications can be fatal 1

Step 3: TIPS (For Failed Medical/Angioplasty)

TIPS is indicated when medical therapy and angioplasty fail to control symptoms or portal hypertension:

• Decompresses portal pressure and reduces sinusoidal congestion 4
• Use covered stents preferentially—they demonstrate superior patency rates (80% at 1 year, 33.3% at 5 years) compared to bare stents (52.9% at 1 year, 20% at 5 years) 2
• Covered stents require fewer re-interventions (0.67 vs 1.65 procedures per patient over 5 years) 2
• MPN patients require more frequent re-interventions regardless of stent type 2

TIPS serves as an effective bridge to transplantation in acute liver failure cases 3, 4

Step 4: Liver Transplantation (Rescue Therapy)

Reserve transplantation for:

• Failure of all prior interventions 1
• Acute liver failure presentation (though TIPS bridging should be attempted first) 3
• Post-transplant survival in BCS is comparable to other indications, even in those with acute liver failure and multiorgan failure 3

Emerging Evidence on Direct Oral Anticoagulants

While the 2016 EASL guidelines recommend VKAs 1, recent 2026 data suggests DOACs (rivaroxaban, dabigatran) may be effective alternatives with comparable patency rates (79.3% at 1 year vs 83.5% for VKA, p=0.269) and similar major bleeding rates after percutaneous recanalization 5. However, this remains investigational and VKAs remain the guideline-recommended standard until prospective trials confirm DOAC safety and efficacy.

Critical Pitfalls to Avoid

• Do not delay anticoagulation while awaiting complete thrombophilia work-up—start immediately upon diagnosis
• Do not stop anticoagulation—it is lifelong regardless of intervention success 3
• Do not skip treatment of underlying MPN—this significantly impacts outcomes 1
• Do not use the stepwise algorithm rigidly in acute liver failure—these patients may require urgent TIPS or transplantation 3
• Do not assume pregnancy is contraindicated—maternal outcomes are favorable, though fetal outcomes remain poor 3